Dyadic International, Inc. (DYAI): Price and Financial Metrics

Dyadic International, Inc. (DYAI): $1.75

0.02 (+1.16%)

POWR Rating

Component Grades













Add DYAI to Watchlist
Sign Up

Industry: Biotech



in industry

DYAI Stock Summary

  • DYAI has a higher market value than merely 12.67% of US stocks; more precisely, its current market capitalization is $49,414,163.
  • For DYAI, its debt to operating expenses ratio is greater than that reported by only 0.48% of US equities we're observing.
  • DYAI's price/sales ratio is 19.77; that's higher than the P/S ratio of 93.92% of US stocks.
  • If you're looking for stocks that are quantitatively similar to DYADIC INTERNATIONAL INC, a group of peers worth examining would be PSNL, ENTX, TARS, EYEN, and SDGR.
  • Visit DYAI's SEC page to see the company's official filings. To visit the company's web site, go to www.dyadic.com.

DYAI Valuation Summary

  • DYAI's price/sales ratio is 17.7; this is 247.06% higher than that of the median Healthcare stock.
  • Over the past 46 months, DYAI's price/sales ratio has gone down 55.5.

Below are key valuation metrics over time for DYAI.

Stock Date P/S P/B P/E EV/EBIT
DYAI 2023-01-20 17.7 3.5 -3.8 -3.2
DYAI 2023-01-19 16.9 3.4 -3.6 -3.0
DYAI 2023-01-18 16.8 3.3 -3.6 -3.0
DYAI 2023-01-17 18.3 3.6 -3.9 -3.3
DYAI 2023-01-13 18.6 3.7 -3.9 -3.4
DYAI 2023-01-12 16.9 3.4 -3.6 -3.0

DYAI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DYAI has a Quality Grade of D, ranking ahead of 6.48% of graded US stocks.
  • DYAI's asset turnover comes in at 0.074 -- ranking 281st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows DYAI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.074 0.193 -1.227
2021-03-31 0.056 0.120 -0.849
2020-12-31 0.049 0.110 -0.565
2020-09-30 0.049 0.056 -0.409
2020-06-30 0.048 0.009 -0.292
2020-03-31 0.042 0.115 -0.263

DYAI Price Target

For more insight on analysts targets of DYAI, see our DYAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.00 Average Broker Recommendation 1.5 (Moderate Buy)

DYAI Stock Price Chart Interactive Chart >

Price chart for DYAI

DYAI Price/Volume Stats

Current price $1.75 52-week high $4.28
Prev. close $1.73 52-week low $1.12
Day low $1.70 Volume 31,600
Day high $1.75 Avg. volume 23,450
50-day MA $1.47 Dividend yield N/A
200-day MA $2.20 Market Cap 49.99M

Dyadic International, Inc. (DYAI) Company Bio

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

DYAI Latest News Stream

Event/Time News Detail
Loading, please wait...

DYAI Latest Social Stream

Loading social stream, please wait...

View Full DYAI Social Stream

Latest DYAI News From Around the Web

Below are the latest news stories about DYADIC INTERNATIONAL INC that investors may wish to consider to help them evaluate DYAI as an investment opportunity.

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced during management’s Q3 earnings call, it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein re

Yahoo | January 24, 2023

Dyadic Announces Sale of Equity Interest in Alphazyme

JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it received approximately $1.27 million in connection with the sale of its equity interest in Alphazyme LL

Yahoo | January 19, 2023

Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USAJUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effect

Yahoo | January 4, 2023

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s anticipated First-In-Human clinical trial designed to demonstrate clinical safety and immune response in humans for its DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate.The C1-cell produced RBD-C-tag antigen strongly binds ACE2 receptors in vitro. Adjuvanted RBD-C-tag-based vaccine ca

Yahoo | December 14, 2022

Analysts Offer Insights on Healthcare Companies: Satsuma Pharmaceuticals (STSA) and Dyadic International (DYAI)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Satsuma Pharmaceuticals (STSA – Research Report) and Dyadic International (DYAI – Research Report) with bullish sentiments. Satsuma Pharmaceuticals (STSA) In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Satsuma Pharmaceuticals, with a price target of $13.00. The company's shares closed last Monday at $0.79. According to TipRanks.

Brian Anderson on TipRanks | November 14, 2022

Read More 'DYAI' Stories Here

DYAI Price Returns

1-mo 40.00%
3-mo -24.57%
6-mo -38.38%
1-year -53.70%
3-year -68.53%
5-year 22.38%
YTD 42.28%
2022 -72.79%
2021 -15.99%
2020 3.86%
2019 174.07%
2018 35.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7039 seconds.